A drug used with encorafenib to treat melanoma that has spread or cannot be removed by surgery and has a certain mutation (change) in the BRAF gene. It is also being studied in the treatment of other types of cancer. Binimetinib blocks proteins called MEK1 and MEK2, which may help keep cancer cells from growing. It is a type of kinase inhibitor. Also called Mektovi. US Brand Name(s): Mektovi. FDA Approved: Yes
Are you looking for or in search of FDA approved “Binimetinib tablets use in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for melanoma. Need Access of “Binimetinib tablets” for oral use for oral use, get in touch with our healthcare professional.
Binimetinib, also known as Mektovi and ARRY-162, is an anti-cancer small molecule that was developed by Array Biopharma to treat various cancers. Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. Inappropriate activation of the pathway has been shown to occur in many cancers. In June 2018 it was approved by the FDA in combination with encorafenib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma
Binimetinib is approved to be used with encorafenib to treat: Melanoma that cannot be removed by surgery or has spread to other parts of the body. It is used in patients whose cancer has a certain mutation in the BRAF gene. Binimetinib is also being studied in the treatment of other types of cancer.